Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma

被引：0
|
作者：
Wiernik, P. H.
Lossos, I. S.
Tuscano, J.
Justice, G.
Vose, J. M.
Pietronigro, D.
Takeshita, K.
Ervin-Haynes, A.
Zeldis, J.
Habermann, T.
机构：
[1] New York Med Coll, Bronx, NY USA
[2] Univ Miami, Miami, FL USA
[3] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
[4] Pacific Coast Hematol Oncol Med Grp, Fountain Valley, CA USA
[5] Univ Nebraska, Omaha, NE 68182 USA
[6] Celgene Corp, Summit, NJ USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8052
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999)
    Morschhauser, Franck
    Cartron, Guillaume
    Thieblemont, Catherine
    Solal-Celigny, Philippe
    Haioun, Corinne
    Bouabdallah, Reda
    Lamy, Thierry
    Milpied, Noel
    Le Gouill, Steven
    Feugier, Pierre
    Wenger, Michael K.
    Wassner-Fritsch, Elisabeth
    Asikanius, Elina
    Salles, Gilles Andre
    BLOOD, 2011, 118 (21) : 1562 - 1563
  • [22] RESULTS FROM A PHASE II STUDY (BO20999) OF RO5072759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA
    Cartron, G.
    Thieblemont, C.
    Solal-Celigny, P.
    Morschhauser, F.
    Haioun, C.
    Bouabdallah, R.
    Wenger, M.
    Salles, G.
    ANNALS OF ONCOLOGY, 2011, 22 : 131 - 132
  • [23] A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results.
    Fehniger, Todd A.
    Larson, Sarah
    Trinkaus, Kathryn
    Siegel, Marilyn J.
    DiPersio, John F.
    Cashen, Amanda F.
    Hurd, David D.
    Blum, Kristie A.
    Bartlett, Nancy L.
    BLOOD, 2008, 112 (11) : 899 - 900
  • [24] Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
    Christian, Beth A.
    Huang, Ying
    Ayyappan, Sabarish
    Baiocchi, Robert A.
    Brammer, Jonathan E.
    Epperla, Narendranath
    Jaglowski, Samantha
    William, Basem M.
    Awan, Farrukh T.
    Maddocks, Kami J.
    Blum, Kristie A.
    BLOOD, 2019, 134
  • [25] Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
    Phillips, Tycel
    Chan, Henry
    Tam, Constantine S.
    Tedeschi, Alessandra
    Johnston, Patrick
    Oh, Sung Yong
    Opat, Stephen
    Eom, Hyeon-Seok
    Allewelt, Heather
    Stern, Jennifer C.
    Tan, Ziwen
    Novotny, William
    Huang, Jane
    Trotman, Judith
    BLOOD ADVANCES, 2022, 6 (11) : 3472 - 3479
  • [26] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphoma - results of a multicentre Phase II study
    Josting, A
    Sieniawski, M
    Staak, JO
    Glossmann, JP
    Diehl, V
    Engert, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S245 - S245
  • [27] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [28] Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study
    Abramson, Jeremy S.
    Takvorian, Ronald W.
    Fisher, David C.
    Feng, Yang
    Jacobsen, Eric D.
    Brown, Jennifer R.
    Barnes, Jeffrey A.
    Neuberg, Donna S.
    Hochberg, Ephraim P.
    LEUKEMIA & LYMPHOMA, 2013, 54 (09) : 1915 - 1920
  • [29] Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymhoma
    Maddocks, Kami J.
    Awan, Farrukh T.
    Huang, Ying
    Ayyappan, Sabarish
    Baiocchi, Robert A.
    Epperla, Narendranath
    Jaglowski, Samantha
    William, Basem M.
    Blum, Kristie A.
    Christian, Beth A.
    BLOOD, 2018, 132
  • [30] Phase II study of oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma: Final results.
    Oki, Y
    McLauhlin, P
    Pro, B
    Hagemeister, FH
    Bleyer, A
    Loyer, E
    Younes, A
    BLOOD, 2004, 104 (11) : 684A - 684A
12345